HER2 testing study for several cancer types
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at a test called HER2 IHC (a way to check for a protein called HER2 on tumor cells) in people with certain cancers: non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), gynecological cancers (cervical, endometrial, ovarian), and urothelial cancer (UC). It aims to see how well the test works in different patients. You may join if you have enough stored tumor tissue from a biopsy or surgery done within the past 5 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with one of these cancers: non-small cell lung cancer, biliary tract cancer, gynecological cancers (cervical, endometrial, or ovarian), or urothelial cancer.
- Your diagnosis was made between January 1, 2023 and September 30, 2025.
- You have stored tumor tissue (from a biopsy or surgery) that is less than 5 years old and enough for at least 15 slides.
- You do not have a history of other cancers besides the ones listed above.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether HER2, a protein linked to some cancers, is found in different gynecologic tumors. It tests stored tumor tissue from women in Brazil to learn more about this marker.
This study is looking at how common HER2 gene changes are in people with advanced non-small cell lung cancer (NSCLC) and how these changes affect treatment. By joining, you help researchers learn more about personalized care for this type of lung cancer.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This trial studies a more precise way to measure HER2 levels in breast cancer tissue. It may help identify patients whose cancer is HER2-low or HER2-zero, so they can get more targeted treatment.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This trial tests a vaccine designed to help the immune system fight remaining HER2-positive breast cancer cells after standard treatment. It is for people who have completed at least six months of HER2-targeted therapy and still have a high risk of the cancer coming back.
Hear when a new Pan-tumor(NSCLC, GYN Cancers, BTC and UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.